Recent Updates
Recently added Catalysts
SKYE Positive Sentiment

Expert Panel with Skye CEO + Obesity Specialist

Monday, March 10, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: At the South by Southwest conference, Skye CEO Punit Dhillon and Dr. Beverly Tchang discussed the importance of achieving sustainable weight loss. They highlighted recent scientific advancements and the potential of combination therapies, particularly focusing on the role of CB1 inhibition in obesity treatment.
Price reaction · baseline $2.63 (2025-03-07 close) · hit pre-market · clean, no other SKYE news in the window
day 0 close · peak
-3.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Discussion on sustainable weight loss outcomes
  • Focus on emerging scientific advancements
  • Exploration of combination therapies
  • Potential benefits of CB1 inhibition

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
24.3%
average across 4 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
Nimacimab
Phase 2 · Obesity

Full Press Release Details

On this South by Southwest conference panel, Punit Dhillon and Clinical Advisory Board Member Dr. Beverly Tchang, MD participate in a discussion about the need for improved sustainable weight loss outcomes, emerging scientific advancements, combination therapies, and the possibilities of CB1 inhibition.

Frequently Asked Questions

What was the focus of the Skye panel discussion?

The panel focused on sustainable weight loss outcomes and scientific advancements.

Who participated in the panel at SXSW?

Punit Dhillon and Dr. Beverly Tchang were the panel participants.

What therapies were discussed for obesity?

The discussion included emerging combination therapies and CB1 inhibition.

What is CB1 inhibition?

CB1 inhibition refers to blocking cannabinoid receptors to aid weight loss.

ShareAdd on Google
Tags: SKYE Viatris Investor Conferences Healthcare Skye Punit Dhillon obesity CB1 inhibition weight loss
Last updated: Mar 10, 2025

Biotech snapshot

Cash runway
$10M liquidity · $2M/mo burn
~4 mo
High dilution risk
Lead asset
NimacimabPhase 2
Obesity →

Catalyst track record

+84%
best trade around SKYE's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SKYE.

See every catalyst's timing & PoA →